#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    B-cell small lymphocytic lymphoma recurrent Chondrodystrophy Spinal muscular atrophy Aplastic anaemia Acute myeloid leukaemia refractory Follicular lymphoma stage II Autologous haematopoietic stem cell transplant Ependymoma Anal fistula Homocystinuria Asthma Chronic cutaneous lupus erythematosus Leukaemia Univentricular heart Ovarian cancer stage IV More trials…

    Learn about Rare Diseases

    Leiomyosarcoma recurrent – Diagnostics Rosai-Dorfman syndrome – Diagnostics Primary immunodeficiency syndrome – Diagnostics Progressive supranuclear palsy – Trials in Disease Breast angiosarcoma metastatic – Basic Information Hyperoxaluria – Trials in Disease Breast angiosarcoma – Diagnostics Hypereosinophilic syndrome – Trials in Disease Alagille syndrome – Basic Information Carcinoid syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    DUVELISIB BENZYLPENICILLIN POTASSIUM Leflunomide Metoprolol Succinate Melphalan Hydrochloride Lamivudine Lutetium (177Lu)-Neobomb1 XYLOMETAZOLINE HYDROCHLORIDE Crizotinib GSK4524101A ABBV-CLS-628 Pemafibrate Sodium Nitroprusside Dihydrate Tng462 L-PROLINE Flecainide VAMIFEPORT TRIHYDROCHLORIDE Blood And Related Products Roflumilast Intestifix More therapies…

    Learn about Your Condition

    Milk allergy Obsessive-compulsive disorder Thromboembolectomy Complicated appendicitis Phenylketonuria Optic atrophy Pain in extremity H1N1 influenza Portal hypertension Hyperoxaluria Petit mal epilepsy Obesity Familial mediterranean fever Haemophilia Acute respiratory failure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Type IIa hyperlipidaemia

  • Lerodalcibep for Heterozygous Familial Hypercholesterolemia in Children and Adolescents 6 to 17 Years Old

    Recruiting

    3 1
    Investigated Drugs:
    • Lerodalcibep
    Norway

  • A Study of Enlicitide for Safety and Effectiveness in Children and Adolescents with Heterozygous Familial Hypercholesterolemia

    Recruiting

    4 1
    Investigated Diseases:
    • Type IIa hyperlipidaemia
    Investigated Drugs:
    • Enlicitide Chloride
    Belgium Czechia Finland France Germany Italy +4

  • Study on Inclisiran, Alirocumab, and Rosuvastatin for Children with Familial Hypercholesterolemia

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Alirocumab
    • Inclisiran
    • Rosuvastatin
    Poland

  • Study on the Safety and Effectiveness of Inclisiran in Children Aged 2 to Under 12 with Homozygous Familial Hypercholesterolemia

    Recruiting

    3 1 1
    Investigated Diseases:
    • Type IIa hyperlipidaemia
    Investigated Drugs:
    • Inclisiran
    Austria France Germany Greece The Netherlands Spain

  • Study on Long-Term Safety of Inclisiran for Patients with Familial Hypercholesterolemia Who Completed Previous Adolescent Studies

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Type IIa hyperlipidaemia
    Investigated Drugs:
    • Inclisiran
    Czechia France Germany Greece Hungary Italy +6

  • Study on the Safety and Effectiveness of Inclisiran for Children Aged 6 to Under 12 with Familial Hypercholesterolemia

    Recruiting

    3 1 1
    Investigated Drugs:
    • Inclisiran
    Austria Belgium Czechia France Germany Greece +6
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!